ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
68 736,82
-0,77%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ChemoCentryx Inc (CCXI)

  7. ChemoCentryx Inc (CCXI) Actualités

CCXI

ChemoCentryx (CCXI)

ChemoCentryx Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CCXI
DateHeureSourceTitreSymboleSociété
25/10/202201h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CCXIChemoCentryx Inc
20/10/202215h28Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CCXIChemoCentryx Inc
20/10/202215h27Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:CCXIChemoCentryx Inc
20/10/202215h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CCXIChemoCentryx Inc
20/10/202215h05PR Newswire (US)AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXNASDAQ:CCXIChemoCentryx Inc
20/10/202214h41Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CCXIChemoCentryx Inc
17/10/202214h30GlobeNewswire Inc.ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsNASDAQ:CCXIChemoCentryx Inc
07/10/202222h36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CCXIChemoCentryx Inc
05/10/202214h30GlobeNewswire Inc.ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:CCXIChemoCentryx Inc
14/09/202223h32Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CCXIChemoCentryx Inc
12/09/202217h14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CCXIChemoCentryx Inc
31/08/202223h08Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CCXIChemoCentryx Inc
24/08/202214h30GlobeNewswire Inc.ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical ConferencesNASDAQ:CCXIChemoCentryx Inc
09/08/202215h40TipRanksAnalysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI) and ATI Physical Therapy (ATIP)NASDAQ:CCXIChemoCentryx Inc
09/08/202214h30GlobeNewswire Inc.ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference CallNASDAQ:CCXIChemoCentryx Inc
04/08/202215h12Dow Jones NewsChemoCentryx Shares Soar Premarket on Amgen Takeover DealNASDAQ:CCXIChemoCentryx Inc
04/08/202214h00PR Newswire (US)AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASHNASDAQ:CCXIChemoCentryx Inc
02/08/202222h05GlobeNewswire Inc.ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022NASDAQ:CCXIChemoCentryx Inc
05/07/202214h30GlobeNewswire Inc.ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent DirectorNASDAQ:CCXIChemoCentryx Inc
06/06/202216h15TipRanksH.C. Wainwright Sticks to Its Buy Rating for ChemoCentryx (CCXI)NASDAQ:CCXIChemoCentryx Inc
06/06/202214h30GlobeNewswire Inc.ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CCXIChemoCentryx Inc
31/05/202222h05GlobeNewswire Inc.ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology ConferencesNASDAQ:CCXIChemoCentryx Inc
31/05/202214h30GlobeNewswire Inc.ChemoCentryx Announces Changes to its Board of DirectorsNASDAQ:CCXIChemoCentryx Inc
22/05/202210h46TipRanksCan ChemoCentryx Control Challenging Capital Complications?NASDAQ:CCXIChemoCentryx Inc
18/05/202214h30GlobeNewswire Inc.ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis SuppurativaNASDAQ:CCXIChemoCentryx Inc
16/05/202214h30GlobeNewswire Inc.ChemoCentryx to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:CCXIChemoCentryx Inc
11/05/202214h30GlobeNewswire Inc.ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated VasculitisNASDAQ:CCXIChemoCentryx Inc
10/05/202222h35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CCXIChemoCentryx Inc
09/05/202209h26TipRanksRaymond James Maintains Their Buy Rating on ChemoCentryx (CCXI)NASDAQ:CCXIChemoCentryx Inc
09/05/202204h18TipRanksChemoCentryx (CCXI) Receives a Buy from Stifel NicolausNASDAQ:CCXIChemoCentryx Inc
 Showing the most relevant articles for your search:NASDAQ:CCXI

Dernières Valeurs Consultées

NASDAQ
BRIL
UNSW
ELETETH
Elementeum
EU
I491T
I491T
BIT
UC4ST4
Unicredit Bank
EU
1786T
1786T
BMF
DI1F34
DI1F34 - Janeiro 2034
NASDAQ
FMMQSX
Smid Energy Portfolio Se...
ASX
SUNJOF
BOV
AVLL3F
Alphaville ON
BOV
PTNT3M
PETTENATI ON
LQID
AAVEBTC
BIT
UB51NH
Unicredit Bank
LSE
VX32
Citi Fun 25
EU
INCE9
Casam Etf CE9 Inav
BIT
F17164
Vontobel Financial Produ...
NASDAQ
SABS
SAB Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés